Doctors And GLP-1 Users Respond To Trump's 'Fat Drugs' Comments

Key Points:

• The use of GLP-1 medications, originally for Type 2 diabetes but now also for obesity and heart disease, has surged in the U.S., with 11% of adults reporting usage in 2024, up from 3% previously.
• President Donald Trump has referred to GLP-1 drugs as "fat shots" or "fat drugs," language criticized by medical professionals and users as stigmatizing, fatphobic, and dismissive of the medications' broad health benefits.
• Healthcare experts emphasize that GLP-1s address complex health conditions beyond weight loss, including diabetes control, heart disease risk reduction, and inflammation, and criticize the government's limited Medicaid coverage for these medications.
• Critics argue that Trump's terminology perpetuates harmful obesity stigma, framing obesity as a moral failing rather than a public health issue influenced by societal factors like food deserts and lack of safe exercise environments.
• GLP-1 users highlight the medication's life-changing effects on their health and stress that weight loss requires significant lifestyle changes, rejecting the notion that these drugs are an "easy" fix.